Background {#Sec1}
==========

Cancer is the leading cause of death worldwide, accounting for 8.2 million deaths in 2012. Chemotherapy is a major component of cancer therapy. However chemotherapy-induced nausea and vomiting (CINV) are common, affecting approximately 70--80% of patients who receive chemotherapy, and can be debilitating \[[@CR1]\]. CINV cause significant anxiety \[[@CR2], [@CR3]\]; decrease quality of life \[[@CR4], [@CR5]\]; and can result in dehydration, electrolyte imbalance \[[@CR6], [@CR7]\], and hospital admission \[[@CR8]\].

Serotonin (5-HT~3~) receptor antagonists are antiemetic medications that act by inhibiting the vagal nerves in the central nervous system and intestinal mucosa that trigger the emetic reflex \[[@CR6], [@CR9]--[@CR11]\]. Examples of first-generation 5-HT~3~ receptor antagonists include dolasetron, granisetron, and ondansetron, while palonosetron is a second-generation receptor antagonist \[[@CR12]\]. These treatments can be administered orally, subcutaneously, or intravenously. Previous systematic reviews have found that 5-HT~3~ receptor antagonists are effective for treating nausea and vomiting that occur after chemotherapy \[[@CR13]--[@CR16]\]. As such, 5-HT~3~ receptor antagonists are recommended as the first-line of treatment for CINV in both adults and children \[[@CR9]\].

Although 5-HT~3~ receptor antagonists are effective in reducing nausea and vomiting, concerns have been raised that they may be associated with increased risk of arrhythmia. Some evidence suggests that they prolong the QT interval on electrocardiography \[[@CR17], [@CR18]\], which is associated with an increased risk of serious ventricular arrhythmias (e.g., torsades de pointes). In vitro studies have indicated that 5-HT~3~ receptor antagonists block voltage-dependent sodium channels and human ether-a-go-go-related gene potassium channels (cardiac ion channels), with the magnitude and type of electrocardiographic change depending on the particular drug. The US Food and Drug Administration \[[@CR19]\] and Health Canada (a division of the Canadian federal government) \[[@CR20]\] have published warnings on the safety of dolasetron but no warnings have appeared for other 5-HT~3~ receptor antagonists. Information about cardiac risks cannot be gleaned from previous systematic reviews of 5-HT~3~ receptor antagonists \[[@CR13]--[@CR16]\] because cardiac safety was not examined in those studies. This systematic review was undertaken, at the request of Canadian policy-makers from Health Canada, to determine the comparative safety and effectiveness of 5-HT~3~ receptor antagonists for patients undergoing chemotherapy.

Methods {#Sec2}
=======

Protocol {#Sec3}
--------

A systematic review protocol was drafted, revised, registered in the PROSPERO database (CRD42013003564), and published in a peer-reviewed, open-access journal \[[@CR21]\]. Because the full methods have already been reported (Additional file [1](#MOESM1){ref-type="media"}), they are described only briefly below. We used the PRISMA extension to network meta-analysis (NMA) to report our results (Additional file [2](#MOESM2){ref-type="media"}) \[[@CR22]\] and our analysis was conducted according to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidance \[[@CR23]\].

Data sources and searches {#Sec4}
-------------------------

The primary information sources were MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, which were searched from inception until 11 December 2015. The full literature search for MEDLINE has been published previously \[[@CR21]\]. To supplement the primary sources, we scanned the reference lists of included studies and relevant reviews \[[@CR24]--[@CR27]\], and searched conference abstracts and trial registries.

Study selection, data extraction, and quality assessment {#Sec5}
--------------------------------------------------------

Studies involving patients of any age undergoing chemotherapy and receiving a 5-HT~3~ receptor antagonist (i.e., dolasetron, granisetron, ondansetron, palonosetron, ramosetron, tropisetron) alone or combined with steroids (dexamethasone, methylprednisolone, prednisone) were included, regardless of publication status, duration of administration of the intervention, or duration of follow-up. Studies published in languages other than English were excluded.

After a calibration exercise, pairs of reviewers independently screened the titles and abstracts of citations and the full-text articles of potentially relevant studies, and then abstracted data from included studies. Disagreements were resolved through consensus or the involvement of an arbitrator (ACT). The following types of data were abstracted from the included studies a priori: study characteristics, patient characteristics, and outcomes. The primary outcome of interest, as identified by policy-makers with Health Canada, was the number of patients experiencing arrhythmia. Secondary outcomes included the numbers of patients experiencing QTc prolongation, QRS interval prolongation, death, sudden cardiac death, delirium, no nausea, no vomiting, no CINV, and severe vomiting.

Randomized controlled trials (RCTs), non-RCTs, and controlled before--after studies were assessed for quality and risk of bias using the Cochrane Effective Practice and Organisation of Care risk-of-bias tool \[[@CR28]\]. Cohort studies were assessed using the Newcastle--Ottawa Scale \[[@CR29]\]. The quality of reporting of harm outcomes was appraised using the McMaster Quality Assessment Scale of Harm (McHarm) tool \[[@CR30]\]. Potential conflicts of interest were recorded for all studies. Pairs of reviewers independently appraised methodological quality and conflicts were resolved through discussion.

Data synthesis and analysis {#Sec6}
---------------------------

Random-effects meta-analysis and NMA were conducted. Meta-analysis utilizes summary point estimates derived from all participants enrolled in a trial, allowing for reliable investigation of treatment effects. NMA allows for the comparison of multiple treatments in a comprehensive analysis and the determination of the best treatment among several competing treatments, including those that have never been compared in a head-to-head study \[[@CR31]\].

For outcomes for which two or more studies comparing two interventions were available, we conducted a meta-analysis for each outcome. We assessed dichotomous outcomes and estimated the treatment effect for each pairwise comparison using the odds ratio (OR) and a 95% confidence interval (CI). We excluded studies that reported zero events across all treatment arms. We anticipated that treatment effects would vary according to patient and study characteristics, and therefore used a random-effects model, estimating the between-study variance with the restricted maximum likelihood method \[[@CR32]\]. Statistical heterogeneity was quantified with the I^2^ statistic \[[@CR33]\], whereas clinical and methodological heterogeneity was assessed subjectively by the study team.

Before embarking on the NMA for each outcome, we drew a network diagram to ensure that the included studies formed a connected network. Potential effect modifiers, specifically, age (adults and elderly versus children) and type of chemotherapy (cisplatin versus other), were identified before NMA was performed and separate network diagrams were drawn with edges colored according to the potential effect modifiers, to ensure balance across treatment comparisons \[[@CR34]\]. Random-effects NMA was then conducted using the *network* command in Stata 13.0 \[[@CR35], [@CR36]\]. Predictive intervals were calculated to observe the range within which the effect estimate would lie should another study be available \[[@CR37]\].

The primary analysis was limited to RCTs, with non-randomized studies included in an additional analysis to evaluate the robustness of the results. Subgroup analysis was conducted to determine whether the results changed according to the potential effect modifiers. We used the design-by-treatment interaction model \[[@CR38], [@CR39]\] to evaluate consistency over the entire network, accounting for potential disagreement both between designs (e.g., two-arm versus three-arm trials) and between direct and indirect evidence. When we identified statistically significant global inconsistency, we examined local inconsistency in each closed loop of the network using the loop-specific method \[[@CR40], [@CR41]\]. We checked inconsistent loops for potential data abstraction errors, as suggested by the loop-specific method; if such errors were identified, we repeated the analyses. Statistically significant inconsistency and important heterogeneity were explored with subgroup and sensitivity analyses. Similar to the pairwise meta-analysis, all NMAs were performed within a frequentist framework with a random-effects model assuming a common within-network heterogeneity variance across all comparisons, estimated with the restricted maximum likelihood method \[[@CR40], [@CR41]\]. Ondansetron was considered usual care in NMAs for which a placebo was missing. Given that it is clinically reasonable to expect the same between-study heterogeneity variance for the same class of interventions, we assumed that all treatment comparisons within the network were associated with the same magnitude of heterogeneity. The surface under the cumulative ranking (SUCRA) curve was used to rank the safety and effectiveness of the various 5-HT~3~ receptor antagonists \[[@CR42]\] and displayed using the rank-heat plot \[[@CR43]\].

We conducted sensitivity analyses to ensure that poor-quality studies did not bias the results. Specifically, we conducted separate analyses for RCTs with low risk of bias on the randomization component, the allocation concealment component, or the blinding component, as well as analyses in which the RCTs were combined with other study designs. Selective outcome reporting and reporting bias (e.g., small-study effects) were assessed using the comparison-adjusted funnel plot for outcomes with at least 10 studies in the network, coding treatments from oldest to newest \[[@CR34]\].

Results {#Sec7}
=======

Literature search {#Sec8}
-----------------

After screening 9226 citations and 970 full-text articles, we included 299 studies (Additional file [3](#MOESM3){ref-type="media"}: Appendix A) that enrolled a total of 58,412 patients (Fig. [1](#Fig1){ref-type="fig"}). Six of these studies were conference abstracts that reported relevant unpublished data \[Adel et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carreca et al. 2007, Kadota et al. 2007, Piyush 2011\]. The 299 studies were reported in 295 primary publications. An additional 18 companion reports were used for supplementary material only.Fig. 1Study flow chart

Study and patient characteristics {#Sec9}
---------------------------------

The included studies were published between 1985 and 2015, with the largest proportion (based on 5-year intervals) appearing between 1995 and 1999, and nearly half were conducted in Europe (Table [1](#Tab1){ref-type="table"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix B). More than 80% of the studies used an RCT design, and more than 40% involved multiple centers. The most commonly examined 5-HT~3~ receptor antagonist was ondansetron. More than 60% of the studies were limited to adults (age ≥ 18 years) (Table [2](#Tab2){ref-type="table"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix C). Lung cancer was the most common diagnosis, and more than half of the chemotherapy regimens included cisplatin. Concomitant radiotherapy was reported in less than 5% of the studies.Table 1Summary of study characteristicsStudy characteristicsNumber of studies^a^ (*n* = 299)Percentage of studiesYear of publication 1985--198931.00 1990--19947324.41 1995--199910434.78 2000--20045016.72 2005--20093411.37 2010--20153511.71Geographic region Europe12441.47 North America7926.42 Asia6521.74 Multi-continent196.35 South America41.34 Africa20.67 Australia00.00 Not reported62.01Study design RCT24682.27 NRCT3311.04 CBA10.33 Cohort196.35Study conduct period 1980--1989175.69 1990--19996923.08 2000--20094013.38 2010--2013124.01 Not reported16153.85Duration of follow-up^b^ 18127.1 2103.3 3258.4 4103.3 57324.4 6196.4 73612.0 \>1 Week3311.0 Not reported124.0Interventions examined: frequency^c^ Serotonin antagonists: reported as administered alone (administered with corticosteroid)  Ondansetron115 (69)38.46 (23.08)  Granisetron88 (55)29.43 (18.39)  Tropisetron23 (9)7.69 (3.01)  Dolasetron19 (7)6.35 (2.34)  Ramosetron11 (6)3.68 (2.01)  Palonosetron14 (22)4.68 (7.36) Comparator antiemetics:  Metoclopramide217.0  Metoclopramide + steroid186.0  Steroid31.0  Chlorpromazine + steroid20.7  Prochlorperazine20.7  Azasetron + steroid10.3  Chlorpromazine10.3  Metopimazine + steroid10.3  Prochlorperazine + steroid10.3 Serotonin antagonists given with other antiemetic:  Ondansetron + steroid + metoclopramide62.1  Granisetron + steroid + metoclopramide62.0  Ondansetron + metoclopramide20.7  Granisetron + metoclopramide10.4  Ondansetron + metopimazine10.4  Tropisetron + metopimazine10.4  Granisetron + steroid + prochlorperazine10.4  Ondansetron + steroid + prochlorperazine10.4  Palonosetron + steroid + prochlorperazine10.4  Tropisetron + steroid + metoclopramide10.4  Placebo or no treatment165.67Outcomes reported: frequency^d^ Nausea20869.6 Vomiting24782.6 CINV11739.1 Arrhythmia217.0 Delirium144.7 Mortality4113.7 Sudden cardiac death31.0 QT interval258.4Setting Multi-center12842.8 Single-center6923.1 Not specified/not reported10133.8*CBA* controlled before--after, *CINV* chemotherapy-induced nausea and vomiting, *NRCT* non-randomized controlled trial, *RCT* randomized controlled trial^a^Includes unpublished data from conference abstracts and trial protocols (Adel et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carreca et al. 2007, Kadota et al. 2007, Piyush 2011)^b^ Duration is in days unless otherwise noted^c^ Multiple interventions and comparators examined across the studies^d^ Multiple interventions and outcomes reported per study Table 2Summary of patient characteristicsPatient characteristicsNumber of studies (*n* = 299)^a,\ b^Percentage of studiesNumber of patients58,412Mean (median sample size)197 (105)^c^Mean % female53.1^d^Age category Adults and elderly (aged ≥18 years)19264.21 Adults only (aged ≥18 to ≤65 years)5618.73 Children only (aged \<18 years)258.36 All ages103.34 Children and adults (aged ≤65 years)82.68 Not reported82.68Cancer type^e^ Lung and respiratory14448.16 Breast11036.79 Gynecological9832.78 Hematological9130.43 Unspecified or unknown8729.10 Head and neck8729.10 Gastrointestinal8628.76 Genitourinary8127.09 Sarcoma4715.72 Not reported4314.38 Nervous system134.35 Skin113.68 Optic51.67 Germ cell51.67 Other31.00 Adenocarcinoma20.67 Musculoskeletal10.33Chemotherapy details Cisplatin administered^f^17759.20 Cisplatin dose ≥ 50 mg/m^2^11638.80 Concomitant radiotherapy124.01 Adjuvant144.68 Neoadjuvant41.34Patient background details History of motion sickness196.35 History of CINV299.70*CINV* chemotherapy induced nausea and vomiting^a^Includes unpublished data from conference abstracts and trial protocols (Adel et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carrec et al. 2007, Kadota et al. 2007, Piyush 2011)^b^Except where indicated otherwise^c^One study did not report sample size (*n* = 1)^d^Eighteen studies did not report female population size (*n* = 18)^e^The majority of studies included patients with different diagnoses^f^Includes the 116 studies with a cisplatin dose ≥ 50 mg/m^2^

Methodological quality and risk of bias results {#Sec10}
-----------------------------------------------

Two hundred and forty-six of the studies were assessed with the Cochrane Effective Practice and Organisation of Care risk-of-bias tool (Additional file [3](#MOESM3){ref-type="media"}: Appendices D, E). Overall, more than half of the studies were assessed as unclear on all of the following components: random sequence generation, allocation concealment, baseline outcome measure similarities between treatment groups, blinding, contamination, selective outcome reporting, and other bias.

The 19 cohort studies were assessed using the Newcastle--Ottawa Scale. More than half of the studies did not ensure the outcome of interest (e.g., incidence of nausea) was present at the beginning of the study, control for potential confounders, or report the follow-up duration (Additional file [3](#MOESM3){ref-type="media"}: Appendix F).

With regard to sources of funding, 153 of the 299 studies did not report the source of funding, 127 were funded by pharmaceutical companies, 17 were publicly funded, and two reported no funding was received. Reporting bias and small-study effects were not observed across the comparison-adjusted funnel plots for all outcomes (Additional file [3](#MOESM3){ref-type="media"}: Appendix G).

Results of statistical analysis {#Sec11}
-------------------------------

### Number of patients experiencing harms {#Sec12}

NMA for the primary outcome of arrhythmia was attempted using three RCTs (*n* = 627 adults) investigating dolasetron, granisetron, palonosetron, and/or granisetron + dexamethasone (Fig. [2](#Fig2){ref-type="fig"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix H). A fourth RCT was excluded from the analysis because it reported zero events in all treatment arms \[[@CR44]\]. The NMA showed no statistically significant effects (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix H). The safest treatment according to the SUCRA was granisetron (83% probability, Fig. [3](#Fig3){ref-type="fig"}). None of the three RCTs examined the same intervention so pairwise meta-analysis was not feasible. The individual results of each trial were not statistically significant, as follows: granisetron versus dolasetron (*n* = 311 patients, OR = 0.21, 95% CI = 0.02--1.84), granisetron + dexamethasone versus granisetron (*n* = 266 patients, OR = 3.12, 95% CI = 0.12--80.39), and palonosetron versus granisetron (*n* = 50 patients, OR = 1.59, 95% CI = 0.58--4.30).Fig. 2Network plots for all network meta-analyses of the primary analysis. *Abbreviations*: *DOLA* dolasetron, *STER* steroid, *GRAN* granisetron, *DEX* dexamethasone, *METO* metoclopramide, *ONDA* ondansetron, *PALO* palonosetron, *PLAC* placebo, *RAMO* ramosetron, *TROP* tropisetron. \*ONDA + DEX and PALO + DEX included only children Table 3Statistically significant results of network meta-analysis in randomized controlled trialsTreatment comparisonNumber of studiesNMA estimate OR (95% CI)^a^MA estimate OR (95% CI)Arrhythmia -- 3 RCTs, 4 (inconsistency not applicable^b^) No statistically significant resultsMortality -- 8 RCTs, 7 treatments, 4823 adults No statistically significant resultsEvaluation of inconsistency using the design-by-treatment interaction modelChi-squared test: 1.06*P-*value: 0.79Degrees of freedom: 3Heterogeneity: 0.00QTc prolongation -- 4 RCTs, 7 treatments, 3358 children and adults (inconsistency not applicable^b^) Ondansetron + dexamethasone vs dolasetron + dexamethasone10.34 (0.24*--*0.47)0.34 (0.24*--*0.47)Number of patients without nausea -- 44 RCTS, 12 treatments plus placebo, 11,664 adults Ondansetron + steroid vs ondansetron81.96 (1.59*--*2.41)2.16 (1.45*--*3.23) Ondansetron + steroid vs granisetron12.00 (1.63*--*2.45)21.00 (3.35*--*131.51) Ondansetron + steroid vs dolasetronNA2.09 (1.47*--*2.97)NA Ondansetron + steroid vs dolasetron + steroidNA0.44 (0.20*--*0.96)NA Ondansetron + steroid vs palonosetronNA1.60 (1.06*--*2.41)NA Ondansetron + steroid vs tropisetron + steroid12.40 (1.49*--*3.88)7.20 (2.03*--*25.51) Ondansetron + steroid vs placeboNA337.68 (18.89*--*6035.72)NA Granisetron + steroid vs ondansetronNA1.91 (1.55*--*2.34)NA Granisetron + steroid vs granisetron61.95 (1.62*--*2.34)1.96 (1.54*--*2.50) Granisetron + steroid vs dolasetronNA2.04 (1.44*--*2.87)NA Granisetron + steroid vs dolasetron + steroidNA0.43 (0.20*--*0.93)NA Granisetron + steroid vs palonosetronNA1.55 (1.04*--*2.33)NA Granisetron + steroid vs tropisetron + steroid12.34 (1.45*--*3.77)7.20 (1.29*--*40.05) Granisetron + steroid vs placeboNA328.52 (18.40*--*5864.44)NA Ondansetron vs dolasetron + steroidNA0.22 (0.10*--*0.48)NA Ondansetron vs palonosetron + steroidNA0.53 (0.39*--*0.73)NA Ondansetron vs tropisetron + steroidNA0.29 (0.13*--*0.62)NA Ondansetron vs ramosetron + steroidNA0.35 (0.19*--*0.64)NA Ondansetron vs placeboNA172.34 (9.67*--*3070.30)NA Granisetron vs dolasetron + steroidNA0.22 (0.10*--*0.47)NA Granisetron vs palonosetron + steroidNA0.52 (0.39*--*0.70)NA Granisetron vs tropisetron + steroidNA0.28 (0.13*--*0.61)NA Granisetron vs ramosetron + steroidNA0.34 (0.19*--*0.62)NA Granisetron vs placebo1168.85 (9.51*--*2996.71)169.00 (9.52*--*2999.80) Dolasetron vs dolasetron + steroid10.21 (0.10*--*0.42)0.21 (0.10*--*0.42) Dolasetron vs palonosetron + steroidNA0.50 (0.33*--*0.76)NA Dolasetron vs tropisetron + steroidNA0.27 (0.12*--*0.61)NA Dolasetron vs ramosetron + steroidNA0.33 (0.17*--*0.63)NA Dolasetron vs placeboNA161.31 (8.95*--*2907.94)NA Dolasetron + steroid vs palonosetronNA3.65 (1.68*--*7.94)NA Dolasetron + steroid vs palonosetron + steroidNA2.39 (1.06*--*5.39)NA Dolasetron + steroid vs tropisetron + steroidNA5.49 (2.27*--*13.27)NA Dolasetron + steroid vs ramosetron + steroidNA3.19 (1.29*--*7.85)NA Dolasetron + steroid vs placeboNA771.35 (39.35*--*15,120.97)NA Palonosetron vs tropisetron + steroidNA0.35 (0.15*--*0.83)NA Palonosetron vs ramosetron + steroidNA0.43 (0.22*--*0.86)NA Palonosetron vs placeboNA211.46 (11.64*--*3841.31)NA Palonosetron + steroid vs tropisetron + steroidNA2.30 (1.35*--*3.91)NA Palonosetron + steroid vs placeboNA323.08 (17.93*--*5821.31)NA Tropisetron + steroid vs tropisetron + steroid20.24 (0.13*--*0.44)0.24 (0.13*--*0.44) Tropisetron + steroid vs ramosetron + steroidNA0.29 (0.14*--*0.60)NA Tropisetron + steroid vs placeboNA140.45 (7.63*--*2585.40)NA Tropisetron + steroid vs placeboNA597.18 (30.37*--*11,744.01)NA Ramosetron + steroid vs ramosetron + steroid10.49 (0.31*--*0.78)0.48 (0.29*--*0.79) Ramosetron + steroid vs placeboNA242.02 (13.10*--*4471.01)NA Ramosetron + steroid vs placeboNA490.92 (26.08*--*9241.08)NAEvaluation of inconsistency using the design-by-treatment interaction modelChi-squared test: 15.91*P-*value: 0.1955Degrees of freedom: 12Heterogeneity: 0.00Number of patients without vomiting -- 63 RCTs, 12 treatments plus placebo, 15,460 adults Ondansetron + steroid vs ondansetron92.46 (1.80*--*3.37)2.47 (1.52*--*4.03) Ondansetron + steroid vs granisetron12.35 (1.70*--*3.25)21.00 (3.35*--*131.51) Ondansetron + steroid vs dolasetronNA2.83 (1.78*--*4.51)NA Ondansetron + steroid vs tropisetron12.95 (1.76*--*4.94)7.20 (2.03*--*25.51) Ondansetron + steroid vs placeboNA31.56 (11.42*--*87.23)NA Granisetron + steroid vs ondansetronNA2.31 (1.66*--*3.21)NA Granisetron + steroid vs granisetron82.21 (1.64*--*2.96)2.40 (1.21*--*4.75) Granisetron + steroid vs dolasetronNA2.66 (1.66*--*4.27)NA Granisetron + steroid vs tropisetron12.77 (1.65*--*4.66)34.52 (1.83*--*650.54) Granisetron + steroid vs placeboNA29.64 (10.74*--*81.82)NA Ondansetron vs dolasetron + steroidNA0.46 (0.24*--*0.89)NA Ondansetron vs palonosetron20.59 (0.39*--*0.89)0.44 (0.27*--*0.73) Ondansetron vs palonosetron + steroidNA0.33 (0.18*--*0.59)NA Ondansetron vs tropisetron + steroidNA0.32 (0.12*--*0.85)NA Ondansetron vs ramosetron + steroidNA0.37 (0.17*--*0.83)NA Ondansetron vs placebo312.82 (4.85*--*33.94)11.02 (3.30*--*36.84) Granisetron vs dolasetron + steroidNA0.48 (0.25*--*0.94)NA Granisetron vs palonosetron30.62 (0.42*--*0.92)0.69 (0.48*--*0.98) Granisetron vs palonosetron + steroidNA0.35 (0.20*--*0.62)NA Granisetron vs tropisetron + steroidNA0.34 (0.13*--*0.90)NA Granisetron vs ramosetron + steroidNA0.39 (0.18*--*0.87)NA Granisetron vs placebo113.44 (5.02*--*35.96)78.00 (6.24*--*974.67) Dolasetron vs dolasetron + steroid10.40 (0.20*--*0.80)0.21 (0.09*--*0.50) Dolasetron vs palonosetron10.51 (0.32*--*0.83)0.55 (0.36*--*0.85) Dolasetron vs palonosetron + steroidNA0.29 (0.15*--*0.57)NA Dolasetron vs tropisetron + steroidNA0.28 (0.10*--*0.79)NA Dolasetron vs ramosetron + steroidNA0.32 (0.14*--*0.78)NA Dolasetron vs placeboNA11.14 (3.94*--*31.49)NA Dolasetron + steroid vs tropisetronNA2.61 (1.20*--*5.69)NA Dolasetron + steroid vs placeboNA27.92 (8.62*--*90.43)NA Palonosetron vs tropisetronNA2.02 (1.13*--*3.63)NA Palonosetron vs placeboNA21.65 (7.60*--*61.72)NA Palonosetron + steroid vs tropisetronNA3.62 (1.78*--*7.37)NA Palonosetron + steroid vs ramosetronNA2.24 (1.02*--*4.91)NA Palonosetron + steroid vs placeboNA38.78 (12.56*--*119.76)NA Tropisetron vs tropisetron + steroid20.27 (0.11*--*0.64)0.27 (0.13*--*0.57) Tropisetron vs ramosetron + steroidNA0.31 (0.13*--*0.77)NA Tropisetron vs placeboNA10.70 (3.69*--*31.01)NA Tropisetron + steroid vs placeboNA39.86 (10.09*--*157.37)NA Ramosetron vs placebo117.30 (6.20*--*48.30)10.45 (2.21*--*49.38) Ramosetron + steroid vs placeboNA34.31 (10.33*--*113.92)NAEvaluation of inconsistency using the design-by-treatment interaction modelChi-squared test: 22.14*P-*value: 0.1387Degrees of freedom: 16Heterogeneity: 0.10Number of patients without CINV -- 27 RCTs, 10 treatments, 10,924 adults Ondansetron + steroid vs ondansetron12.16 (1.62*--*2.87)1.96 (1.12*--*3.42) Ondansetron + steroid vs granisetronNA2.17 (1.73*--*2.72)NA Ondansetron + steroid vs palonosetron + steroidNA0.81 (0.67*--*0.98)NA Ondansetron + steroid vs tropisetronNA4.18 (1.99*--*8.77)NA Ondansetron + steroid vs placeboNA365.96 (20.44*--*6553.02)NA Granisetron + steroid vs ondansetronNA2.23 (1.69*--*2.93)NA Granisetron + steroid vs granisetron62.24 (1.83*--*2.74)2.35 (1.88*--*2.94) Granisetron + steroid vs palonosetron + steroidNA0.84 (0.70*--*0.99)NA Granisetron + steroid vs tropisetronNA4.31 (2.07*--*9.01)NA Granisetron + steroid vs placeboNA378.03 (21.15*--*6756.45)NA Ondansetron vs palonosetron + steroidNA0.38 (0.27*--*0.52)NA Ondansetron vs ramosetron + steroidNA0.31 (0.16*--*0.59)NA Ondansetron vs placeboNA169.61 (9.48*--*3035.34)NA Granisetron vs palonosetron + steroidNA0.37 (0.29*--*0.49)NA Granisetron vs ramosetron + steroidNA0.31 (0.16*--*0.60)NA Granisetron vs placebo1168.85 (9.51*--*2996.64)169.00 (9.52*--*2999.80) Palonosetron vs placeboNA165.47 (6.55*--*4182.08)NA Palonosetron + steroid vs tropisetronNA5.16 (2.43*--*10.97)NA Palonosetron + steroid vs placeboNA452.19 (25.18*--*8121.41)NA Tropisetron vs ramosetronNA0.35 (0.14*--*0.83)NA Tropisetron vs ramosetron + steroidNA0.16 (0.06*--*0.42)NA Tropisetron vs placeboNA87.64 (4.53*--*1696.76)NA Ramosetron vs ramosetron + steroid10.46 (0.29*--*0.73)0.55 (0.34*--*0.89) Ramosetron vs placeboNA253.30 (13.55*--*4734.53)NA Ramosetron + steroid vs placeboNA546.71 (28.58*--*10,456.90)NAEvaluation of inconsistency using the design-by-treatment interaction modelChi-squared test: 11.95*P*-value: 0.0631Degrees of freedom: 6Heterogeneity: 0.00Number of patients experiencing severe vomiting -- 10 RCTs, 5 treatments, 917 adults Ondansetron vs granisetron40.65 (0.45*--*0.94)0.63 (0.43*--*0.93) Ondansetron vs placebo30.16 (0.04*--*0.70)0.16 (0.04*--*0.70) Ramosetron vs placeboNA0.18 (0.03*--*0.95)NAEvaluation of inconsistency using the design-by-treatment interaction modelChi-squared test: 0.33*P*-value: 0.5628Degrees of freedom: 1Heterogeneity: 0.00*CI* confidence interval, *CINV* chemotherapy-induced nausea and vomiting, *MA* meta-analysis, *NA* not applicable, *NMA* network meta-analysis, *OR* odds ratio, *RCT* randomized controlled trial^a^ Meta-analysis was not conducted for treatment comparisons where only one trial was included; in that situation, the direct estimate was obtained from the single trial^b^ Number of interventions included in NMA is greater than number of RCTs Fig. 3Rank-heat plot including adults in randomized controlled trials. *Abbreviations*: *DOLA* dolasetron, *STER* steroid, *GRAN* granisetron, *DEX* dexamethasone, *METO* metoclopramide, *ONDA* ondansetron, *PALO* palonosetron, *PLAC* placebo, *RAMO* ramosetron, *TROP* tropisetron, *No Vx* number of patients without vomiting, *No Nx* number of patients without nausea, *No Vx&Nx* number of patients without chemotherapy-induced nausea and vomiting, *Severe Vx* number of patients experiencing severe vomiting

NMA for the secondary outcome of mortality was conducted with eight RCTs (*n* = 4823 adults) investigating dolasetron, granisetron, ondansetron (usual care), palonosetron, tropisetron, granisetron + dexamethasone, metoclopramide + dexamethasone, ondansetron + dexamethasone, and/or palonosetron + dexamethasone (Fig. [2](#Fig2){ref-type="fig"}). A ninth study was excluded from the analysis because it reported zero events in all treatment arms \[[@CR45]\], and another study was excluded because it was not connected to the network \[[@CR46]\]. The NMA showed no statistically significant effects (Table [3](#Tab3){ref-type="table"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix H). The safest treatment according to the SUCRA was palonosetron + dexamethasone (93% probability, Fig. [3](#Fig3){ref-type="fig"}). In addition, three pairwise meta-analyses were possible for the following treatment comparisons, which were not statistically significant: palonosetron + dexamethasone versus granisetron + dexamethasone (three RCTs, *n =* 2638 adults, OR = 0.33, 95% CI = 0.09--1.18), ondansetron + dexamethasone versus ondansetron (two RCTs, *n =* 313 adults, OR = 0.53, 95% CI = 0.11--2.58), and palonosetron + dexamethasone versus ondansetron + dexamethasone (two RCTs, *n =* 1101 adults, OR = 0.33, 95% CI = 0.04--2.78).

NMA for the secondary outcome QTc prolongation included four RCTs investigating dolasetron + dexamethasone, granisetron, granisetron + dexamethasone, ondansetron (usual care), ondansetron + dexamethasone, palonosetron, and palonosetron + dexamethasone (*n =* 3358 children and adults, Fig. [2](#Fig2){ref-type="fig"}). A fourth RCT was excluded from the analysis because it reported zero events in all treatment arms \[[@CR38]\]. The NMA showed that patients taking ondansetron + dexamethasone administration had statistically significantly lower odds of QTc prolongation compared to patients taking dolasetron + dexamethasone (OR = 0.34, 95% CI = 0.24--0.47) (Table [3](#Tab3){ref-type="table"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix H). The safest treatment according to the SUCRA was palonosetron + dexamethasone (83% probability). None of the four RCTs examined the same intervention so pairwise meta-analysis was not feasible. Consistent with the NMA results, only one of the individual results of the four RCTs was statistically significant (ondansetron + dexamethasone versus dolasetron + dexamethasone, *n =* 696 patients*,* OR = 0.34, 95% CI = 0.24--0.47). The other results were as follows: ondansetron versus granisetron (*n =* 1056 patients, OR = 7.92, 95% CI = 0.44--143.67), palonosetron versus granisetron (*n =* 597 patients, OR = 2.80, 95% CI = 0.06--141.54), palonosetron + dexamethasone versus granisetron + dexamethasone (*n =* 1119 patients, OR = 0.84, 95% CI = 0.42--1.68), palonosetron versus ondansetron (*n =* 773 patients, OR = 0.35, 95% CI = 0.02--6.42), and palonosetron + dexamethasone versus ondansetron + dexamethasone (*n =* 330 children, OR = 0.20, 95% CI = 0.01--4.10).

NMA and pairwise meta-analysis were not feasible for the secondary outcomes of sudden cardiac death, delirium, and QRS interval prolongation because only one RCT was available for each of these outcomes. For sudden cardiac death, the results were not statistically significant between ondansetron and ondansetron + dexamethasone (*n =* 213 patients, OR = 2.73, 95% CI = 0.11--67.80). For delirium, there were no statistically significant results for any of the treatment comparisons, including metoclopramide + dexamethasone versus granisetron (*n =* 361 patients, OR = 4.14, 95% CI = 0.86--19.93), metoclopramide + dexamethasone versus granisetron + dexamethasone (*n =* 478 patients, OR = 4.07, 95% CI = 0.85--19.59), or granisetron versus granisetron + dexamethasone (*n =* 597 patients, OR = 0.98, 95% CI = 0.01--7.10). For QRS interval prolongation, the available RCT only reported results for more than 24 h of chemotherapy; ondansetron administered on days 1--7 plus dexamethasone resulted in statistically significantly fewer patients experiencing a prolonged QRD interval when compared to dolasetron + dexamethasone (OR = 0.29, 95% CI = 0.19--0.48).

When the studies reporting these harms were appraised using the McHarm tool (Additional file [3](#MOESM3){ref-type="media"}: Appendices I, J), the majority were assessed as unclear or partially fulfilling all 15 criteria other than active collection of mode of harm, timing and frequency of harms collection, use of standard scales for collection of harms data, reporting of whether harms encompassed all patients or a sample of patients, and number of harmful events reported for each group, which were commonly scored unclear overall.

### Number of patients without nausea {#Sec13}

NMA for the secondary outcome of the number of patients without nausea within 24 h was attempted with 47 RCTs and 11,778 patients, as well as a NMA including 51 studies with 12,188 patients (including randomized and non-randomized studies), yet statistically significant inconsistency was observed for both NMAs.

NMA for the 44 RCTs (*n* = 11,664 adults) investigating 12 treatments plus placebo (Fig. [2](#Fig2){ref-type="fig"}, Additional file [4](#MOESM4){ref-type="media"}: Appendix A) showed that all of the treatments were significantly superior to placebo in increasing the proportion of patients without nausea (Table [3](#Tab3){ref-type="table"}, Additional file [3](#MOESM3){ref-type="media"}: Appendices K, L). In this analysis, dolasetron + steroid had the highest SUCRA (Fig. [3](#Fig3){ref-type="fig"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix M), with a 95% probability of being the most effective agent, followed closely by tropisetron + steroid (89% probability). The same results were observed in another subgroup analysis for patients who received cisplatin chemotherapy (23 RCTs and 6259 patients) (Additional file [3](#MOESM3){ref-type="media"}: Appendix N). In an analysis of three pediatric RCTs of four treatments (granisetron, ondansetron, palonosetron, tropisetron; *n* = 293 children), palonosetron was statistically significantly superior to ondansetron, and granisetron was statistically significantly superior to tropisetron. Palonosetron had the highest SUCRA (88% probability).

A sensitivity analysis was conducted with 14 RCTs assessed as having a low risk of randomization bias (*n* = 4970 patients, 10 treatments). Ondansetron was superior to dolasetron and granisetron, while all other comparisons were superior to ondansetron. However, only palonosetron + steroid, granisetron + steroid, ondansetron + steroid, and ramosetron + steroid were statistically significantly superior to ondansetron (Additional file [3](#MOESM3){ref-type="media"}: Appendix N). Ramosetron + steroid had the highest SUCRA (94% probability). Another sensitivity analysis was conducted that included 14 RCTs with a low risk of allocation concealment bias (*n* = 4199 patients, nine treatments). All treatments except dolasetron increased the proportion of patients without nausea versus ondansetron. However, only palonosetron + steroid, granisetron + steroid, ondansetron + steroid, and dolasetron + steroid were statistically significant. Dolasetron + steroid had the highest SUCRA (95% probability). A third sensitivity analysis was conducted including 11 RCTs with a low risk of blinding bias (*n* = 3858 patients, seven treatments). Compared to ondansetron, all treatments except dolasetron and granisetron increased the proportion of patients without nausea. However, only granisetron + steroid, ondansetron + steroid, and palonosetron were statistically significant. Palonosetron had the highest SUCRA (99% probability).

NMA was conducted with 31 RCTs (*n =* 8108 patients, 30 treatments plus placebo) for the number of patients without nausea more than 24 h after chemotherapy. All of the dosing schedules and medications were superior to placebo, but only the following schedules were statistically significant﻿: ondansetron + steroid on day 1 of chemotherapy and at least one subsequent day, palonosetron on day 1 of chemotherapy, ondansetron + steroid on day 1 of chemotherapy and at least one subsequent day + metoclopramide on days 2--5 of chemotherapy, and tropisetron + steroid on day 1 of chemotherapy and at least one subsequent day. The last of these schedules had the highest SUCRA (96% probability). Notably, dolasetron + steroid was not included in this NMA because none of the studies reported this intervention.

### Number of patients without vomiting {#Sec14}

NMA for the secondary outcome of number of patients without vomiting within 24 h after chemotherapy was conducted with 71 RCTs (*n* = 16,300 adults, 12 treatments plus placebo; Additional file [4](#MOESM4){ref-type="media"}: Appendix B). All of the treatments were statistically significantly superior to placebo for this outcome (Additional file [3](#MOESM3){ref-type="media"}: Appendix O). Palonosetron + steroid had the highest SUCRA (90% probability; Additional file [3](#MOESM3){ref-type="media"}: Appendix P), followed closely by tropisetron + steroid (79% probability). The same results were observed in another analysis that included 75 randomized and non-randomized studies (*n* = 16,710 patients, 12 treatments plus placebo), as well as subgroup analysis including 63 RCTs with 15,460 adults, and 12 treatments plus placebo (Figs [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix Q). Similar results were observed in another subgroup analysis including 69 RCTs and 15,742 patients who received cisplatin chemotherapy (12 treatments plus placebo); however, in this subgroup analysis, dolasetron + steroid and tropisetron + steroid both had a higher SUCRA (89% probability) than palonosetron + steroid (78% probability). In an analysis of five pediatric RCTs including a total of 411 children and testing six treatments plus placebo (granisetron, ondansetron, ondansetron + steroid, palonosetron, tropisetron, placebo), granisetron and tropisetron were statistically significantly superior to placebo, and granisetron had the highest SUCRA (84% probability).

A sensitivity analysis was conducted including 21 RCTs assessed as having a low risk of randomization bias (*n =* 6549 patients, 10 treatments plus placebo). Relative to placebo, all treatments increased the proportion of patients without vomiting, although none of the results were statistically significant (Additional file [3](#MOESM3){ref-type="media"}: Appendix Q). The highest SUCRA values were found in palonosetron + steroid (84% probability) and ramosetron + steroid (81% probability). Another sensitivity analysis was conducted including 21 RCTs with a low risk of allocation concealment bias (*n =* 6315 patients, 11 treatments). Relative to ondansetron, all treatments except dolasetron increased the proportion of patients without vomiting. The proportion of patients without vomiting was statistically significantly higher with palonosetron, palonosetron + steroid, and ondansetron + steroid versus ondansetron. Palonosetron + steroid had the highest SUCRA (73% probability). A third sensitivity analysis was conducted including 20 RCTs with a low risk of blinding bias (*n =* 6232 patients, nine treatments plus placebo). Compared with placebo, all treatments statistically significantly increased the proportion of patients without vomiting. The highest SUCRA values were found for palonosetron (81% probability), palonosetron + steroid (81% probability), and ondansetron + steroid (79% probability).

NMA was attempted with 48 RCTs (*n* = 9425 patients) that reported the number of patients without vomiting more than 24 h after chemotherapy. However, there was inconsistency between direct and indirect evidence. Therefore, a subgroup analysis was conducted with 45 RCTs involving only adults (*n* = 8845 patients, 26 treatments plus placebo). All of the dosing schedules and medications were numerically superior to placebo ﻿and there were 21 treatments that were also statistically superior to placebo. However, the following schedules were not statistically significant﻿﻿: ramosetron only on day 1 of chemotherapy, dolasetron only on day 1 and at least one subsequent day, ramosetron + steroid on day 1 and at least one subsequent day, and granisetron + steroid on day 1 and at least one subsequent day. Dolasetron + steroid on day 1 had the highest SUCRA (94% probability) along with palonosetron + steroid on day 1 (94% probability).

### Number of patients without CINV {#Sec15}

NMA was attempted for the secondary outcome of number of patients without CINV within 24 h of chemotherapy including 28 RCTs with 11,252 patients, as well as a second NMA including 26 studies with 10,014 patients (including randomized and non-randomized studies), yet statistically significant inconsistency was observed in both NMAs.

NMA for 27 RCTs involving 10,924 adults (nine treatments plus placebo) was conducted (Fig. [2](#Fig2){ref-type="fig"}, Additional file [4](#MOESM4){ref-type="media"}: Appendix C). All of the treatments were statistically significantly superior to placebo for this outcome (Table [3](#Tab3){ref-type="table"}, Additional file [3](#MOESM3){ref-type="media"}: Appendices K, R). Ramosetron + steroid had the highest SUCRA (93% probability), followed by palonosetron + steroid (91% probability; Fig. [3](#Fig3){ref-type="fig"}, Additional file [3](#MOESM3){ref-type="media"}: Appendix S). Similar results were observed in another subgroup analysis including 15 RCTs and 5250 patients receiving cisplatin chemotherapy (nine treatments plus placebo; Additional file [3](#MOESM3){ref-type="media"}: Appendix T). In another subgroup analysis including eight RCTs for 3066 patients who did not receive cisplatin chemotherapy and seven treatments, palonosetron + steroid, ondansetron + steroid, and granisetron + steroid were statistically significantly superior to ondansetron and had the highest SUCRAs (Additional file [3](#MOESM3){ref-type="media"}: Appendix T).

A sensitivity analysis was conducted including eight RCTs assessed as having a low risk of randomization bias (*n* = 3677 patients, five treatments). Compared to ondansetron, all treatments except granisetron significantly increased the proportion of patients without CINV (Additional file [3](#MOESM3){ref-type="media"}: Appendix T). Palonosetron + steroid had the highest SUCRA (85% probability). A second sensitivity analysis was conducted including five RCTs with a low risk of allocation concealment bias (*n* = 2771 patients, four treatments). Granisetron + steroid, palonosetron + steroid, and ondansetron + steroid increased the proportion of patients without CINV versus ondansetron, yet granisetron + steroid was not statistically significant. Ondansetron + steroid had the highest SUCRA (89% probability).

NMA was conducted with 26 RCTs (*n =* 8851 patients, 22 treatments plus placebo) that reported the number of patients without CINV at more than 24 h after chemotherapy. All treatments reduced the risk of CINV relative to placebo, and the reduction was statistically significant for the following regimens: ondansetron on day 1 of chemotherapy only + steroid on day 1 and at least one subsequent day, granisetron on day 1 only, ondansetron + steroid on day 1 and at least one subsequent day, granisetron on day 1 only + steroid on day 1 and at least one subsequent day, palonosetron on day 1 only, dolasetron on day 1 and at least one subsequent day + steroid on day 1 only, ondansetron + steroid on day 1 and at least one subsequent day with metoclopramide on days 2--5, palonosetron on day 1 only + steroid on day 1 and at least one subsequent day, tropisetron + steroid on day 1 and at least one subsequent day, and ramosetron on day 1 and at least one subsequent day. Ramosetron on day 1 and at least one subsequent day had the highest SUCRA (90% probability), followed by tropisetron + steroid on day 1 and at least one subsequent day (88% probability).

### Number of patients experiencing severe vomiting {#Sec16}

NMA was conducted for the secondary outcome of number of patients experiencing severe vomiting (defined as vomiting five times or more) within 24 h after chemotherapy. In this analysis, 11 RCTs, 1364 adults, and six treatments plus placebo were included (Fig. [2](#Fig2){ref-type="fig"}, Additional file [4](#MOESM4){ref-type="media"}: Appendix D). All treatments were superior to placebo in reducing the risk of severe vomiting, but only ondansetron and ramosetron were statistically significantly superior (Table [3](#Tab3){ref-type="table"}, Additional file [3](#MOESM3){ref-type="media"}: Appendices K, U). Ondansetron + steroid had the highest SUCRA (80% probability), followed closely by ondansetron (73% probability; Additional file [3](#MOESM3){ref-type="media"}: Appendix V). Similar results were observed in a secondary analysis including 13 randomized and non-randomized study designs (*n =* 1600 patients, eight treatments plus placebo), except that tropisetron + steroid had the highest SUCRA (83% probability). The same results as the primary analysis were observed in a subgroup analysis including seven RCTs and 677 adults receiving cisplatin chemotherapy (six treatments plus placebo) (Additional file [3](#MOESM3){ref-type="media"}: Appendix W).

Discussion {#Sec17}
==========

We conducted a systematic review and NMA on 5-HT~3~ receptor antagonists for patients undergoing chemotherapy. Our results suggest that all treatments are relatively safe, but we were unable to conduct an NMA on sudden cardiac death, prolonged QRS interval, or delirium because of a dearth of data. Future RCTs to examine the safety of these treatments should include these important outcomes. As well, the studies included in our NMAs of arrhythmia, QTc prolongation, and mortality did not have a placebo comparator, and we are therefore unable to comment on the safety of these treatments relative to placebo.

Overall, our results suggest that all of these treatments are effective for reducing nausea and vomiting experienced by patients undergoing chemotherapy. According to the rank-heat plot, the treatment that is most likely the safest and most effective is palonosetron + steroid. Our findings can be used by patients and their clinicians to tailor their choice of treatments. For example, if a patient is most concerned about CINV during the first 24 h after chemotherapy, then ramosetron + steroid may be the best choice. Across the effectiveness outcomes, the following treatments ranked as most superior on three effectiveness outcomes during the first 24 h after chemotherapy for adults: ondansetron + steroid, palonosetron + steroid, granisetron + steroid, and ramosetron + steroid. If a patient is most concerned about CINV occurring more than 24 h after chemotherapy, then ramosetron given on day 1 and at least one subsequent day, tropisetron + steroid given on day 1 and at least one subsequent day, or palonosetron given on day 1 + steroid given on day 1 and at least one subsequent day are potentially effective options.

For the outcome of the number of patients without vomiting, some nuances in the results are worth mentioning. In the NMA for the proportion of patients without vomiting more than 24 h after chemotherapy, dolasetron + steroid administered on day 1 of chemotherapy ranked high in the SUCRA analysis. However, dolasetron + steroid did not rank highest in the SUCRA analysis for the proportion of patients without vomiting within 24 h after chemotherapy. This apparent discrepancy might be due to the structure of the different networks. For example, different interventions were included between the studies assessing treatment within 24 h of chemotherapy versus those targeting vomiting more than 24 h after chemotherapy, which might have affected the results. The differing results might also be attributable to heterogeneity, given that some treatment comparisons will have different magnitudes than others included in each NMA.

For the NMA on severe vomiting, the combination of ondansetron + steroid was numerically superior to all of the other treatments, but the results were not statistically significant. This might be due to a lack of power because only one small RCT (*n* = 20 patients) examined ondansetron + steroid versus ondansetron. However, because of the large effect sizes, this treatment ranked high on the SUCRA analysis. Therefore, the SUCRA results for the outcome of severe vomiting should be interpreted with caution.

We are aware of four previous systematic reviews that examined 5-HT~3~ receptor antagonists for nausea and vomiting \[[@CR24]--[@CR27]\]. Only two of these reviews examined harms, such as dizziness, fever, headaches, and constipation \[[@CR26], [@CR27]\]. We included more studies (*n* = 200) and more patients (*n* = 30,864) than any of these reviews (Additional file [3](#MOESM3){ref-type="media"}: Appendix X), but we also excluded some of the studies that were included in those earlier reviews; reasons for those exclusions are presented in Additional file [3](#MOESM3){ref-type="media"}: Appendix Y.

The studies included in our NMAs had some limitations. Most of the studies were small, with an average sample size of 197 patients. This limitation is particularly problematic for assessing harms, because larger sample sizes are required to draw definitive conclusions. Approximately 40% of the included studies were funded by pharmaceutical companies, which may have resulted in funding bias. In addition, random sequence generation, allocation concealment, and blinding were unclear for more than half of the RCTs. All of the studies failed to ensure that the outcome of interest (e.g., no nausea) was present at the start of the study. In addition, few of the included studies reported on the emetogenicity setting (e.g., highly emetogenic chemotherapy). Despite these methodological shortcomings, we did not observe reporting bias or small-study effects in our comparison-adjusted funnel plot analysis for all outcomes.

Our systematic review process also had some limitations. Because of the large number of included studies, revisions to our original protocol \[[@CR21]\] were necessary. For example, we were unable to include all conference abstracts and reports written in languages other than English. Moreover, we did not conduct a sensitivity analysis around the node selection for the NMA, as we assumed that the effects of different doses and durations were identical across treatments. We are now exploring these assumptions in another study \[[@CR47]\]. In addition, clinical practice guidelines recommend prophylaxis with a 5-HT~3~ receptor antagonist, steroid, and a NK1 receptor antagonist, yet none of the included studies examined this combination of treatments. As such, our effectiveness results should be interpreted with caution. As well, NMA should only be attempted when the studies are sufficiently homogenous. As such, we explored whether the transitivity assumption was upheld and found that confounding variables were generally well balanced across the treatment comparisons in our NMA. However, some of the studies may not have reported all important confounding variables so this is a limitation of our study. Although we planned to include non-randomized studies in our analyses of harms, we found only RCTs reporting the outcomes of interest. Finally, we were unable to conduct an analysis stratified by emetogenicity, because of varied reporting of chemotherapy regimens and classification of chemotherapy regimens by type of emetogenic agent over time \[[@CR9]\].

Conclusions {#Sec18}
===========

From this study, we conclude that most 5-HT~3~ receptor antagonists alone or combined with steroids decrease the occurrence of nausea and/or vomiting. Most 5-HT~3~ receptor antagonists were relatively safe when compared with each other, yet none of the studies compared active treatment with placebo for harms. Dolasetron + dexamethasone may prolong the QTc compared to ondansetron + dexamethasone. Additional studies are needed to characterize the cardiac and cognitive safety of these treatments. Until then, it would be prudent for clinicians to obtain baseline electrocardiographic tracings before prescribing these common, effective antiemetics to any patients who are undergoing chemotherapy.
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